COCH · Envoy Medical, Inc. · Executive Compensation
$0.68
+0.00 (+0.00%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Since inception, the Company has historically incurred negative operating cash flows and losses from operations as the Company advances the clinical development of its products and the funding process of clinical FDA trials. These matters raise substantial doubt about the Company's ability to continue as a going concern and although management has developed plans intended to support ongoing operations, such plans do not alleviate the substantial doubt.”View the 10-Q filed Aug 10, 2026
Market Cap
$54.72M
Shares
77.19M
Volume · Oct 2
160.58K
Avg daily vol (3M)
166.2K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Brent T. Lucas | Chief Executive Officer and Director | $462,000 |
| Robert M. Potashnick | Interim Chief Financial Officer | $180,766 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Brent T. Lucas | Chief Executive Officer and Director | $410,509 |
| David R. Wells | Former Chief Financial Officer | $364,583 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Brent T. Lucas | Chief Executive Officer and director | $1,699,524 |
| David R. Wells | Chief Financial Officer | $583,528 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Brent T. Lucas | Chief Executive Officer and director | $265,296 |
| David R. Wells | Chief Financial Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Robert Potashnick | Chief Accounting Officer and Vice President of Finance | Appointed | 2026-08-27 |
| Susan J. Kantor | Class III director | Appointed | 2026-05-18 |
| Brent T. Lucas | Class III director | Appointed | 2026-05-18 |
| Charles S. McKhann | Class I director | Appointed | 2026-04-21 |
| Glen Taylor | Board of Directors | Resigned | 2025-08-26 |
| Robert Potashnick | Interim Chief Financial Officer | Appointed | 2025-06-25 |
| Chuck Brynelsen | Class II director | Appointed | 2025-06-03 |
| Janis Smith-Gomez | Class II director | Appointed | 2025-06-03 |
| David R. Wells | Chief Financial Officer | Terminated | 2025-05-19 |
| Michael Crowe | board of directors | Appointed | 2024-06-11 |
| Dr. Whitney Haring-Smith | board of directors | Resigned | 2024-06-11 |
| Daniel Hirsch | executive officer | Resigned | 2023-10-05 |
| Whitney Haring-Smith | executive officer | Resigned | 2023-10-05 |
| Whitney Haring-Smith | chairman of the Board | Resigned | 2023-10-05 |
| Daniel Hirsch | director | Resigned | 2023-10-05 |
| Priya Cherian Huskins | director | Resigned | 2023-10-05 |
| Diane Dewbrey | director | Resigned | 2023-10-05 |
| David R. Wells | Chief Financial Officer | Appointed | 2023-10-05 |
| Brent Lucas | Chief Executive Officer | Appointed | 2023-10-05 |
| Charles Brynelsen | chairman of the board of directors | Appointed | 2023-10-05 |
| Glen A. Taylor | director | Appointed | 2023-10-05 |
| Mona Patel | director | Appointed | 2023-10-05 |
| Janis Smith-Gomez | director | Appointed | 2023-10-05 |
| Susan J. Kantor | director | Appointed | 2023-10-05 |
| Whitney Haring-Smith | director | Appointed | 2023-10-05 |